Patents by Inventor Kenneth W. Dobie

Kenneth W. Dobie has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Modulation of forkhead box O1A expression
    Patent number: 7807649
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of forkhead box O1A. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding forkhead box O1A. Methods of using these compounds for modulation of forkhead box O1A expression and for treatment of diseases associated with expression of forkhead box O1A are provided, in particular, for methods of treating diabetes.
    Type: Grant
    Filed: April 23, 2007
    Date of Patent: October 5, 2010
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Kenneth W. Dobie, Sanjay Bhanot, Murielle Veniant-Ellison, Richard A. Lindberg, John R. Shutter, Robert McKay, Sanjay K. Pandey
  • Modulation of eIF4E-BP2 expression
    Patent number: 7807652
    Abstract: Compounds, compositions and methods are provided for modulating the expression of eIF4E-BP2. The compositions comprise oligonucleotides, targeted to nucleic acid encoding eIF4E-BP2. Methods of using these compounds for modulation of eIF4E-BP2 expression and for diagnosis and treatment of diseases and conditions associated with expression of eIF4E-BP2 are provided.
    Type: Grant
    Filed: November 21, 2006
    Date of Patent: October 5, 2010
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Sanjay Bhanot, Kenneth W. Dobie, Ravi Jain
  • Modulation of growth hormone receptor expression and insulin-like growth factor expression
    Patent number: 7803781
    Abstract: Compounds, compositions and methods are provided for modulating the expression of growth hormone receptor and/or insulin like growth factor-I (IGF-I). The compositions comprise oligonucleotides, targeted to nucleic acid encoding growth hormone receptor. Methods of using these compounds for modulation of growth hormone receptor expression and for diagnosis and treatment of disease associated with expression of growth hormone receptor and/or insulin-like growth factor-I are provided. Diagnostic methods and kits are also provided.
    Type: Grant
    Filed: February 26, 2004
    Date of Patent: September 28, 2010
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Kenneth W Dobie, Ravi Jain
  • ANTISENSE MODULATION OF KINESIN-LIKE 1 EXPRESSION
    Publication number: 20100240738
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of kinesin-like 1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding kinesin-like 1. Methods of using these compounds for modulation of kinesin-like 1 expression and for treatment of diseases associated with expression of kinesin-like 1 are provided.
    Type: Application
    Filed: February 26, 2010
    Publication date: September 23, 2010
    Applicant: Isis Pharmaceuticals, Inc.
    Inventors: Kenneth W. Dobie, Erich Koller
  • Compositions and their uses directed to Gemin Genes
    Patent number: 7759479
    Abstract: Disclosed herein are compounds, compositions and methods for modulating the expression of a Gemin Gene. Also provided are methods of target validation. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders.
    Type: Grant
    Filed: September 13, 2005
    Date of Patent: July 20, 2010
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Kenneth W. Dobie, Susan M. Freier
  • Modulation of apolipoprotein c-III expression
    Patent number: 7750141
    Abstract: Compounds, compositions and methods are provided for modulating the expression of apolipoprotein C-III. The compositions comprise oligonucleotides, targeted to nucleic acid encoding apolipoprotein C-III. Methods of using these compounds for modulation of apolipoprotein C-III expression and for diagnosis and treatment of disease associated with expression of apolipoprotein C-III are provided.
    Type: Grant
    Filed: April 15, 2004
    Date of Patent: July 6, 2010
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Rosanne M. Crooke, Mark J. Graham, Kenneth W. Dobie
  • MODULATION OF SID-1 EXPRESSION
    Publication number: 20100152280
    Abstract: Compounds, compositions and methods are provided for modulating the expression of SID-1. The compositions comprise oligonucleotides, targeted to nucleic acid encoding SID-1. Methods of using these compounds for modulation of SID-1 expression and for diagnosis and treatment of diseases and conditions associated with expression of SID-1 are provided.
    Type: Application
    Filed: October 24, 2008
    Publication date: June 17, 2010
    Applicant: Isis Pharmaceuticals, Inc.
    Inventors: Kenneth W. Dobie, C. Frank Bennett
  • Modulation of diacylglycerol acyltransferase 2 expression
    Patent number: 7732590
    Abstract: Compounds, compositions and methods are provided for modulating the expression of diacylglycerol acyltransferase 2. The compositions comprise oligonucleotides, targeted to nucleic acid encoding diacylglycerol acyltransferase 2. Methods of using these compounds for modulation of diacylglycerol acyltransferase 2 expression and for diagnosis and treatment of diseases and conditions associated with expression of diacylglycerol acyltransferase 2 are provided.
    Type: Grant
    Filed: February 24, 2005
    Date of Patent: June 8, 2010
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Sanjay Bhanot, Kenneth W. Dobie, Xing-Xian Yu, Brett P. Monia
  • Antisense modulation of kinesin-like 1 expression
    Patent number: 7718628
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of kinesin-like 1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding kinesin-like 1. Methods of using these compounds for modulation of kinesin-like 1 expression and for treatment of diseases associated with expression of kinesin-like 1 are provided.
    Type: Grant
    Filed: December 29, 2006
    Date of Patent: May 18, 2010
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Kenneth W. Dobie, Erich Koller
  • Modulation of RANKL expression
    Patent number: 7700574
    Abstract: Compounds, compositions and methods are provided for modulating the expression of RANKL. The compositions comprise oligonucleotides, targeted to nucleic acid encoding RANKL. Methods of using these compounds for modulation of RANKL expression and for diagnosis and treatment of disease associated with expression of RANKL are provided.
    Type: Grant
    Filed: September 17, 2004
    Date of Patent: April 20, 2010
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Brenda F Baker, C. Frank Bennett, Kenneth W. Dobie, Kathleen Myers, Joshua Finger, Lex M. Cowsert
  • COMPOSITIONS AND THEIR USES DIRECTED TO HBXIP
    Publication number: 20100056607
    Abstract: Disclosed herein are compounds, compositions and methods for modulating the expression of HBXIP in a cell, tissue or animal. Also provided are methods of target validation. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders.
    Type: Application
    Filed: July 18, 2007
    Publication date: March 4, 2010
    Applicant: ISIS PHARMACEUTICALS, INC
    Inventors: Kenneth W. Dobie, Nicholas M. Dean, C. Frank Bennett
  • MODULATION OF STAT 6 EXPRESSION
    Publication number: 20090292009
    Abstract: Compounds, compositions and methods are provided for modulating the expression of STAT 6. The compositions comprise oligonucleotides, targeted to nucleic acid encoding STAT 6. Methods of using these compounds for modulation of STAT 6 expression and for diagnosis and treatment of disease associated with expression of STAT 6 are provided.
    Type: Application
    Filed: July 27, 2009
    Publication date: November 26, 2009
    Applicant: Isis Pharmaceuticals, Inc.
    Inventors: William R. Shanahan, JR., Susan M. Freier, Kenneth W. Dobie
  • MODULATION OF INSULIN LIKE GROWTH FACTOR I RECEPTOR EXPRESSION
    Publication number: 20090286849
    Abstract: The present invention provides compositions and methods for modulating the expression of growth factor gene. In particular, this invention relates to compounds, particularly oligonucleotide compounds, which, in preferred embodiments, hybridize with nucleic acid molecules encoding the Insulin Like Growth Factor I receptor (IGF-I receptor or IGF-IR) and in particular human IGF-IR. Such compounds are exemplified herein to modulate proliferation which is relevant to the treatment of proliferative and inflammatory skin disorders and cancer. It will be understood, however, that the compounds can be used for any other condition in which the IGF-IR is involved including inflammatory condition.
    Type: Application
    Filed: December 22, 2008
    Publication date: November 19, 2009
    Applicant: Antisense Therapeutics Ltd.
    Inventors: Christopher John WRAIGHT, George Arthur Werther, Nicholas M. Dean, Kenneth W. Dobie
  • Modulation of HIF-1 beta expression
    Patent number: 7618947
    Abstract: Compounds, compositions and methods are provided for modulating the expression of HIF1-beta. The compositions comprise oligonucleotides, targeted to nucleic acid encoding HIF1-beta. Methods of using these compounds for modulation of HIF1-beta expression and for diagnosis and treatment of diseases and conditions associated with expression of HIF1-beta are provided.
    Type: Grant
    Filed: August 25, 2005
    Date of Patent: November 17, 2009
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Eric G. Marcusson, Scott W. Henry, Youngsoo Kim, Kenneth W. Dobie
  • Compositions and Their Uses Directed to IL-4R Alpha
    Publication number: 20090281169
    Abstract: Disclosed herein are compounds, compositions and methods for modulating the expression of IL-4R alpha in a cell, tissue or animal. Also provided are methods of target validation. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders related to expression of IL 4R-?, airway hyperresponsiveness, and/or pulmonary inflammation.
    Type: Application
    Filed: April 16, 2009
    Publication date: November 12, 2009
    Applicant: ISIS PHARMACEUTICALS, INC.
    Inventors: James G. Karras, Susan Gregory, Susan M. Freier, Kenneth W. Dobie
  • MODULATION OF TUDOR-SN EXPRESSION
    Publication number: 20090270491
    Abstract: Compounds, compositions and methods are provided for modulating the expression of Tudor-SN. The compositions comprise oligonucleotides, targeted to nucleic acid encoding Tudor-SN. Methods of using these compounds for modulation of Tudor-SN expression and for diagnosis and treatment of diseases and conditions associated with expression of Tudor-SN are provided.
    Type: Application
    Filed: June 19, 2009
    Publication date: October 29, 2009
    Applicant: Isis Pharmaceuticals, Inc.
    Inventors: Nicholas M. Dean, Ming-Yi Chiang, Kenneth W. Dobie
  • COMPOSITIONS AND THEIR USES DIRECTED TO HSP27
    Publication number: 20090264502
    Abstract: Disclosed herein are compounds, compositions and methods for modulating the expression of HSP27 in a cell, tissue or animal. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders.
    Type: Application
    Filed: August 24, 2006
    Publication date: October 22, 2009
    Inventors: C. Frank Bennett, Nicholas M. Dean, Kenneth W. Dobie
  • Modulation of apolipoprotein C-III expression
    Patent number: 7598227
    Abstract: Compounds, compositions and methods are provided for modulating the expression of apolipoprotein C-III. The compositions comprise oligonucleotides, targeted to nucleic acid encoding apolipoprotein C-III. Methods of using these compounds for modulation of apolipoprotein C-III expression and for diagnosis and treatment of disease associated with expression of apolipoprotein C-III are provided.
    Type: Grant
    Filed: April 16, 2003
    Date of Patent: October 6, 2009
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Rosanne M. Crooke, Mark J. Graham, Kristina M. Lemonidis, Kenneth W. Dobie
  • Compositions and their uses directed to thymus and activation-regulated chemokine (TARC)
    Patent number: 7585968
    Abstract: Disclosed herein are compounds, compositions and methods for modulating the expression of TARC in a cell, tissue or animal. Also provided are methods of target validation. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders related to expression of TARC, airway hyperresponsiveness, and/or pulmonary inflammation.
    Type: Grant
    Filed: March 27, 2006
    Date of Patent: September 8, 2009
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: James G. Karras, Kenneth W. Dobie
  • MODULATION OF CHREBP EXPRESSION
    Publication number: 20090209625
    Abstract: Disclosed herein are compounds, compositions, and methods for modulating the expression of ChREBP in a cell, tissue or animal. Also provided are methods of target validation. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and conditions.
    Type: Application
    Filed: May 23, 2007
    Publication date: August 20, 2009
    Inventors: Sanjay Bhanot, Kenneth W. Dobie, Susan F. Murray